Nymox Reports Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH

Nymox Pharmaceutical Corporation

reported a favorable update and recent Safety Monitoring Committee review of safety data for the Company's NX02-0022 reinjection study for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The most recent Safety Monitoring Committee meeting found no significant safety concerns to date. Enrollment in this study at participating investigational sites across the U.S. has passed the 50% accrual level. Trial NX02-0022 is an open label study of the safety and efficacy of NX-1207 reinjection for the treatment of BPH. The study is open to subjects who had previously participated in an NX-1207 BPH study. All patients are given an intraprostatic injection of NX-1207 2.5 mg. The first of two NX-1207 reinjection studies (NX02-0020) was successfully completed in January 2013. Patients with BPH in the earlier NX02-0020 reinjection study received one or two injections of NX-1207 into the prostate. Mean overall improvement in the 192 treated men was 7.6 points in their AUA BPH Symptom Scores (p < .001). The mean duration from the initial injection to the final assessment was 26 months. Ongoing testing of NX-1207 has not shown any evidence of the drug eliciting an immune